Hostname: page-component-6766d58669-kn6lq Total loading time: 0 Render date: 2026-05-16T08:47:16.313Z Has data issue: false hasContentIssue false
  • English
  • Français

Why consider obliterating the mastoid in cholesteatoma surgery anyway? Lessons learnt from changing treatment strategy, preliminary results and future perspectives

Presenting Author: Robert Jan Pauw

Published online by Cambridge University Press:  03 June 2016

Robert Jan Pauw ,
Mick Metselaar ,
Anne van Linge ,
Laura Veder ,
Bas Pullens  and
Marc van der Schroeff
Robert Jan Pauw
Affiliation:
Erasmus MC
Mick Metselaar
Affiliation:
Erasmus MC
Anne van Linge
Affiliation:
Erasmus MC
Laura Veder
Affiliation:
Erasmus MC
Bas Pullens
Affiliation:
Erasmus MC
Marc van der Schroeff
Affiliation:
Erasmus MC
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Learning Objectives: To demonstrate the advantages of mastoid obliteration in cholesteatoma surgery. To emphasize the importance of structured follow-up after cholesteatoma surgery in order to assess both medical and patient reported outcome measures.

Mastoid obliteration in cholesteatoma surgery can decrease the cholesteatoma recurrence rate.

In the Erasmus Medical Center we have implemented canal wall up tympanoplasty with bony obliteration of the mastoid as the treatment strategy of choice for primary or recurrent cholesteatoma. Preliminary results of this treatment strategy will be shown and compared to our previous results with cholesteatoma recurrence and residual rate as primary outcome measures.

Currently, all patients are included in a prospective database that includes not only medical outcome measures like cholesteatome recurrence and residual rate, complication rate and hearing results, but also patient reported outcome measures using general and disease specific questionnaires. An overview of the current standardized follow-up regimen and the outline of the database will be given. A concept version of an interactive cholesteatoma dashboard that allows real time insights in different outcome measures will be demonstrated.